On Medical Treatments & Products Archives

Statement of Dr. Diana Zuckerman on Behalf of the National Center for Health Research FDA Advisory Committee Meeting on AMX0035 for ALS

September 7, 2022 Diana Zuckerman testified on behalf of NCHR at the FDA Advisory Committee hearing about the poor evidence foe Amylyx drug AMX0035 for the treatment of ALS, and how approving this drug would undermine other ALS clinical trials that are underway.

NCHR Agrees with CDC Draft Recommendation to Remove Liraglutide and Pertuzumab from the National Institute for Occupational Safety and Health Hazardous Drugs in Healthcare Settings List

February 15th, 2024: NCHR supports the CDC recommendation to remove Liraglutide and Pertuzumab drugs from the NIOSH List of Hazardous Drugs in Healthcare Settings. We agree that due to the to the drugs’ low bioavailability and limited risk of occupational exposures these drugs are unlikely to pose a harm to healthcare workers.

NCHR’s Comment on EPA’s Proposed Lead and Copper Rule Improvements (LCRI)

February 2024: In its public comment, NCHR supported EPA’s proposed lead and copper rule improvements (LCRI) and suggested strengthening safeguards such as lowering the action lead level to 5 ppb or less, more attention to schools, daycares, and afterschool facilities, better enforcement, and not replacing lead pipes with PVC or other dangerous pipes.

NCHR Comments on USPSTF Draft Recommendations on Interventions for Adolescents with a High Body Mass Index

January 16, 2024: NCHR strongly supports USPSTF’s draft recommendation on using behavioral interventions to manage unhealthy weight gain in adolescents over six years of age with a body mass index at the 95th percentile for their age and sex. More research is needed to clearly show the safety and efficacy of weight loss medications in this patient population.

NCHR Comment on CPSC Proposed Investigation of Smart Toys and Additional Toys Through Child Observations Response

NCHR submitted the only comment to CPSC about their proposed study of young children’s effective use of smart toys. CPSC responded to our previous comment and released a revised request for public comments, clarifying that the study was exploratory. We responded by again urging CPSC to study a larger number of children who are more representative of the U.S. population, to better guide future guidelines for these toys.